Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12831060 | 0.91 | CHRM2 (0.42) | PIK3CDCHRM2ALDH1A1SLC6A4 | |
| SCHEMBL22199516 | 0.88 | CHRM2 (0.40) | PIK3CDCHRM2ALDH1A1SLC6A4 | |
| SCHEMBL22735861 | 0.84 | CHRM2 (0.37) | CHRM2SLC6A4 | |
| SCHEMBL769212 | 0.84 | CA12 (0.39) | CHRM2SLC6A4TLR7 | |
| SCHEMBL1255458 | 0.83 | — | — | |
| SCHEMBL22503168 | 0.83 | PIK3CD (0.50) | PIK3CDALDH1A1SCN9ASLC6A4 | |
| SCHEMBL23101786 | 0.83 | PIK3CD (0.50) | PIK3CDALDH1A1SCN9ASLC6A4 | |
| SCHEMBL25477639 | 0.82 | CA12 (0.50) | CHRM2SLC6A4 | |
| SCHEMBL25478263 | 0.81 | PIK3CD (0.48) | PIK3CDCHRM2ALDH1A1SLC6A4TLR7 | |
| SCHEMBL22735860 | 0.80 | CHRM2 (0.42) | PIK3CDCHRM2ALDH1A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230121233-A1 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121233-A1 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | BAX, PDCD1, PDCD4 | PIK3CD 382/4885CHRM2 4665/4885ALDH1A1 3695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.